Urologix, Inc. ( ULGX)

F1Q2012 (Qtr End 09/30/2011) Earnings Call

November 07, 2011 05:00 pm ET

Executives

Stryker Warren, Jr. - CEO

Brian Smrdel - CFO

Analysts

Presentation

Operator

Good day ladies and gentlemen, and welcome to the Urologix Incorporated fiscal year 2012 first quarter conference call. My name is Shinal and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of the conference. As a reminder, this conference is being recorded for replay purposes. Certain information discussed during this conference call, including answers to your questions, may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those stated or implied in any forward-looking statements due to risks and uncertainties. A detailed discussion of risks and uncertainties may be found in Urologix’s recent Annual Report and Form 10-K for the year ending June 30, 2011 and other documents filed with the Securities and Exchange Commission. Urologix disclaims any obligation to update any forward-looking statements made during the course of this call.

At this time I would turn the call over to Mr. Stryker Warren, Jr. Chief Executive Officer. Please proceed, sir.

Stryker Warren, Jr.

Thank you Shinal and good afternoon to all those joining us today to discuss the company's results for the first quarter of fiscal year 2012. With me are Brian Smrdel, the company's Chief Financial Officer and Greg Fluet, Executive Vice President and Chief Operating Officer of Urologix. Today's call will begin with a review of the recently completed Prostiva transaction. Brian will then review the financial results for the first quarter and I will share an update on the progress we are making on the integration of Prostiva, review our near-term priorities and then offer some thoughts in perspective on the trends in the broader market before opening up the call for questions.

If you liked this article you might like

Urologix's CEO Discusses F4Q2012 Results - Earnings Call Transcript

Urologix's CEO Discusses F3Q2012 Results - Earnings Call Transcript

Urologix's CEO Discusses F2Q2012 Results - Earnings Call Transcript

Urologix's CEO Presents At Lazard Capital Markets 8th Annual Healthcare Conference - Conference Call Transcript

Urologix's CEO Presents At Lazard Capital Markets 8th Annual Healthcare Conference - Conference Call Transcript